Literature DB >> 8523591

Specific binding of human immunodeficiency virus type 1 (HIV-1) Gag-derived proteins to a 5' HIV-1 genomic RNA sequence.

U Geigenmüller1, M L Linial.   

Abstract

We developed an in vitro binding assay to study the specific interaction between human immunodeficiency virus type 1 (HIV-1) RNA and the Gag polyprotein. Binding of the in vitro-expressed protein to in vitro-transcribed RNA was determined by altered migration of the protein in polyacrylamide gels. We found that a Gag precursor lacking the matrix domain bound specifically to HIV-1 RNA, while deletion of both matrix and capsid domains diminished the specificity of binding. Among several regions of HIV-1 RNA tested, strongest binding was seen with the 5'-most 261 nucleotides, while antisense RNA from the same region did not bind.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8523591      PMCID: PMC189864     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Development of avian sarcoma and leukosis virus-based vector-packaging cell lines.

Authors:  A W Stoker; M J Bissell
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Mutations in Rous sarcoma virus nucleocapsid protein p12 (NC): deletions of Cys-His boxes.

Authors:  C Méric; E Gouilloud; P F Spahr
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

3.  A conserved cis-acting sequence in the 5' leader of avian sarcoma virus RNA is required for packaging.

Authors:  R A Katz; R W Terry; A M Skalka
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.

Authors:  A H Kaplan; M Manchester; R Swanstrom
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

6.  Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs.

Authors:  P A Krieg; D A Melton
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

7.  Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates.

Authors:  J F Milligan; D R Groebe; G W Witherell; O C Uhlenbeck
Journal:  Nucleic Acids Res       Date:  1987-11-11       Impact factor: 16.971

8.  Amphotropic retrovirus vector system for human cell gene transfer.

Authors:  J Sorge; D Wright; V D Erdman; A E Cutting
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

9.  Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions.

Authors:  M A Adam; A D Miller
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

10.  Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5' long terminal repeat and the start of the gag gene.

Authors:  S Watanabe; H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

View more
  25 in total

Review 1.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

2.  A heterologous, high-affinity RNA ligand for human immunodeficiency virus Gag protein has RNA packaging activity.

Authors:  J L Clever; R A Taplitz; M A Lochrie; B Polisky; T G Parslow
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Role of the DIS hairpin in replication of human immunodeficiency virus type 1.

Authors:  B Berkhout; J L van Wamel
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

4.  Infectious molecular clones with the nonhomologous dimer initiation sequences found in different subtypes of human immunodeficiency virus type 1 can recombine and initiate a spreading infection in vitro.

Authors:  D C St Louis; D Gotte; E Sanders-Buell; D W Ritchey; M O Salminen; J K Carr; F E McCutchan
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Efficient encapsidation of human immunodeficiency virus type 1 vectors and further characterization of cis elements required for encapsidation.

Authors:  M S McBride; M D Schwartz; A T Panganiban
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  HIV-1 Pr55Gag binds genomic and spliced RNAs with different affinity and stoichiometry.

Authors:  Serena Bernacchi; Ekram W Abd El-Wahab; Noé Dubois; Marcel Hijnen; Redmond P Smyth; Johnson Mak; Roland Marquet; Jean-Christophe Paillart
Journal:  RNA Biol       Date:  2016-11-14       Impact factor: 4.652

7.  The C-terminal p6 domain of the HIV-1 Pr55Gag precursor is required for specific binding to the genomic RNA.

Authors:  Noé Dubois; Keith K Khoo; Shannon Ghossein; Tanja Seissler; Philippe Wolff; William J McKinstry; Johnson Mak; Jean-Christophe Paillart; Roland Marquet; Serena Bernacchi
Journal:  RNA Biol       Date:  2018-08-04       Impact factor: 4.652

8.  RNA structure and packaging signals in the 5' leader region of the human immunodeficiency virus type 1 genome.

Authors:  Jared L Clever; Daniel Miranda; Tristram G Parslow
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

9.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.

Authors:  L Naldini; U Blömer; F H Gage; D Trono; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

10.  Genetic dissociation of the encapsidation and reverse transcription functions in the 5' R region of human immunodeficiency virus type 1.

Authors:  J L Clever; D A Eckstein; T G Parslow
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.